Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy - 24/08/11
Doi : 10.1016/S1470-2045(03)01327-5
Niccolò Bolli, Mauro Di Ianni, Stefano Simonetti, Lorenzo Cerroni, Arcangelo Liso, Brunangelo Falini, Antonio Tabilio, Prof ⁎ 
*Correspondence: Prof Antonio Tabilio, Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, University of Perugia, Policlinico Monteluce Via Brunamonti, 06122 Perugia, Italy. Tel: + 39 075 5783990. Fax: + 39 075 5726449
| NB, MDI, and AL are postgraduate residents and BF and AT are professors of haematology, all in the Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, University of Perugia, Italy. SS is a dermatologist at the Dematology Unit, University of Perugia, Italy. LC is a dermatologist at the Department of Dermatology, Univeristy of Graz, Austria. |
© 2004
Elsevier Ltd. Tous droits réservés.
Vol 5 - N° 1
P. 64-65 - janvier 2004 Retour au numéro
Article précédent
- Myeloid sarcoma of the prostate as first clinical manifestation of acute myeloid leukaemia
- Sebastian Spethmann, Roman Heuer, Helmut Hopfer, Gert Tuinmann
- Complementary and alternative medicine
- Marilynn Larkin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?